{"url_path":"/sec/cgtx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-057545-index.html","accession_number":"0001104659-26-057545","cik":"0001455365","ticker":"CGTX","issuer_name":"COGNITION THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1455365/0001104659-26-057545-index.html","primary_entity_key":"0001455365","primary_entity_name":"COGNITION THERAPEUTICS INC"},"word_count":511,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\n**Exhibit**\n\n \n\n \n\n \n\n**Incorporated by Reference**\n\n \n\n**Filed**\n\n**Number**\n\n \n\n**Exhibit Description**\n\n \n\n**Form**\n\n \n\n**File No.**\n\n \n\n**Exhibit**\n\n \n\n**Filing Date**\n\n \n\n**Herewith**\n\n3.1\n\n​\n\n[Third Amended and Restated Certificate of Incorporation of Cognition Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1455365/000110465921126265/tm2130061d1_ex3-1.htm)\n\n​\n\n8-K\n\n​\n\n001-40886\n\n​\n\n3.1\n\n​\n\n10/14/2021\n\n​\n\n​\n\n3.2\n\n​\n\n[Second Amended and Restated Bylaws of Cognition Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1455365/000155837023008117/cgtx-20230331xex3d1.htm)\n\n​\n\n10-Q\n\n​\n\n001-40886\n\n​\n\n3.1\n\n​\n\n05/04/2023\n\n​\n\n​\n\n3.3\n\n​\n\n[Amendment to the Second Amended and Restated Bylaws of Cognition Therapeutics, Inc.](https://www.sec.gov/Archives/edgar/data/1455365/000155837025003341/cgtx-20241231xex3d3.htm)\n\n​\n\n10-K\n\n​\n\n001-40886\n\n​\n\n3.3\n\n​\n\n03/20/2025\n\n​\n\n​\n\n10.1\n\n​\n\n[Office Lease Agreement between RJ Equities LP and Cognition Therapeutics, Inc., dated July 1, 2017, as amended](cgtx-20260331xex10d1.htm).\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n31.1\n\n \n\n[Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](cgtx-20260331xex31d1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n31.2\n\n \n\n[Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](cgtx-20260331xex31d2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n32.1*\n\n \n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](cgtx-20260331xex32d1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n32.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](cgtx-20260331xex32d2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.DEF\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.LAB\n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n104\n\n​\n\nCover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nX\n\n​\n\n* This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n​\n\n35\n\n[Table of Contents](#TOC)\n\n**SIGNATURES**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\n \n\n**Cognition Therapeutics, Inc.**\n\n \n\n \n\n \n\nDate: May 8, 2026\n\nBy:\n\n/s/ Lisa Ricciardi\n\n \n\n \n\nLisa Ricciardi\n\n \n\n \n\nChief Executive Officer, President and Director\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: May 8, 2026\n\nBy:\n\n/s/ John Doyle\n\n \n\n \n\nJohn Doyle\n\n \n\n \n\nChief Financial Officer\n(Principal Financial and Accounting Officer)\n\n​\n\n​\n\n​\n\n36"}